Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by sah1on Oct 29, 2020 1:55pm
123 Views
Post# 31804492

RE:Custer @ $5

RE:Custer @ $5Dibah, I am thinking a rights issue or a loan from TV with warrants at $5. I can't see just increasing the LoC at this point as this should have been done to prevent the big sp drop but who knows? Equity issue on Nasdaq is only likely to come after Ryplazim approval. The company probably needs $40M or so to get to March. I also figure the financing has to be announced before the Q3 results call. Any thoughts, Dibah, on how the company is going to extend its cash runway to Ryplazim approval and beyond?
<< Previous
Bullboard Posts
Next >>